Number 2

What Number 2 does

Number 2 is a community-led stool donor recruitment programme operated by EnteroBiotix Limited (registered number SC559230, Scotland), recruiting healthy adults aged 18–60 living locally to Aberdeen, Scotland to donate stool for conversion into microbiome-based therapeutic treatments. Prospective donors complete an online eligibility questionnaire via SmartSurvey, attend a screening session at the Human Nutrition Unit of The Rowett Institute (University of Aberdeen), and commit to donating an average of 3–4 days per week either on-site (7am–1pm, Monday–Friday, no appointment required) or via a home donation programme with WhatsApp-coordinated driver collection. The programme applies rigorous donor screening, including blood and stool testing every 30 days, GMC-registered clinician review of health questionnaires, and a quarantine hold on donations until pathogen results clear, in alignment with GDPR and Data Protection Act 2018 requirements. Donor-to-team communication is handled through the proprietary Number 2 Donor / Number 2 Management mobile application, which captures daily health questionnaires and donation photographs.

The underlying business is clinical supply rather than direct therapeutics commercialisation: Number 2 produces rigorously screened biological material that EnteroBiotix converts into treatments targeting C. difficile infections, inflammatory bowel disease, colorectal cancer, Parkinson's disease, and motor neurone disease. Donors receive expense payments for time and travel; no customer-facing pricing applies to the therapeutic output, and revenue mechanics are not disclosed. The marketing and distribution model is fully direct and localised—top-of-funnel channels are the Number2.org website, social media (Facebook, LinkedIn, Twitter), and word-of-mouth testimonials, while physical collection runs through two channels: on-site at The Rowett Institute and home donation via scheduled driver pickup.

The operating entity is small—6 employees, founded in 2020—with no disclosed institutional funding, no enterprise customers, and a single-city operational footprint. Strategically, the programme sits as a vertically integrated upstream supply function for EnteroBiotix's microbiome therapeutics pipeline rather than a standalone commercial business, which is the key framing for any investment thesis.

Name

Number 2

Legal name

EnteroBiotix Limited

Website

https://number2.org

Company type

Private

Operating status

Operating

Headcount range

1–10 employees

Short description

Number 2 is a community-led stool donor recruitment programme in Aberdeen, Scotland (operated by EnteroBiotix Limited) that recruits healthy adults aged 18–60 to supply rigorously screened biological material for microbiome-based therapeutic development.

Ownership category

akta.pro rank

Product category

Microbiome Therapeutics Donor Services

NAICS

Blood and Organ Banks (621991)

SIC

Biological Products, (No Disgnostic Substances) (2836), Services-Medical Laboratories (8071)

akta.pro primary industry

Blood, Organ & Tissue Donation Organizations (BPAGACAJ)

akta.pro secondary industry

Clinical Trial Sample Collection & Site Phlebotomy Services (HLAGACAJ)

Keywords

• Stool donor programme
• Microbiome therapeutics
• Gut microbiome research
• Fecal microbiota donation
• Biotherapeutic development

Headquarters

HQ city

Glasgow

HQ country

United Kingdom

HQ region

Europe

Offices2 records

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Core offering

The Number 2 Donor Programme recruits healthy adults aged 18-60 in Aberdeen, Scotland to donate stool samples that are processed into microbiome-based medicinal treatments for life-threatening diseases such as C. difficile infections, inflammatory bowel disease, colorectal cancer, Parkinson's disease, and motor neurone disease. Donations are collected either on-site at the Human Nutrition Unit of The Rowett Institute (Monday-Friday, 7am-1pm) or via a home collection programme with driver pickup, and are supported by a companion mobile app for daily health questionnaires and donation tracking. The programme is operated by EnteroBiotix Limited (registered number SC559230), with all donor material undergoing rigorous blood and stool screening every 30 days before use in therapeutic development.

Product overview

The Number 2 Donor Programme is a unified stool donation service operated by EnteroBiotix Limited. The programme consists of the Number 2 Donor Programme (the core donor recruitment and stool collection service) and the companion Number 2 Donor and Number 2 Management mobile app. Together they enable healthy donors to contribute stool samples through either in-person donation at The Rowett Institute or home collection, with all donations undergoing rigorous screening for development of microbiome-based medicinal treatments and research.

Differentiator

Problem solved

Functional benefit

Products and services

• Number 2 Donor Programme

Quantifiable outcome

• Donations enable development of treatments for C. difficile infections, inflammatory bowel disease, colorectal cancer, Parkinson's disease, and motor neurone disease

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration2 records

Feature1 record

Partnerships

Two partnerships are on record, tiered core.

• The Rowett InstitutecoreStrategic or Co-development PartnerThe Rowett Institute, University of Aberdeen, serves as the primary operational partner. The Human Nutrition Unit at the institute hosts screening sessions, on-site donations, and routine blood tests. A GMC-registered doctor at the institute reviews donor health questionnaires. The institute provides dedicated toilet facilities for on-site donations and laboratory space for screening procedures.
• EnteroBiotix LimitedcoreOthersEnteroBiotix Limited (registered number SC559230) is the operating company behind the Number 2 Donor Programme. The company develops medicinal treatments from rigorously screened gut microbiome material. EnteroBiotix operates the programme, the Number 2 Donor and Number 2 Management mobile app, and maintains the associated privacy policies and terms of service.

Recent moves5 records

Expansion highlights4 records

Direct peers

• Vedanta Biosciences: Vedanta Biosciences develops defined bacterial consortia for immune-mediated diseases using microbiome-derived therapeutics. It is comparable in developing microbiome-based medicinal treatments for serious diseases, though it focuses on defined synthetic consortia rather than donor-derived material.
• Seres Therapeutics: Seres Therapeutics is a clinical-stage microbiome therapeutics company developing treatments for C. difficile and other indications. It is a direct peer as it relies on microbial consortia or consortia-derived products for therapeutic applications, competing in the same target indications.
• 4D Pharma: 4D Pharma is a UK-based microbiome therapeutics company developing live biotherapeutics for cancer and other diseases. It is a direct peer in the UK microbiome therapeutics landscape, though it was reported to have undergone significant restructuring.
• MaaT Pharma: MaaT Pharma is a French clinical-stage biotechnology company developing microbiome-based therapeutics, particularly for oncology and graft-versus-host disease. It is comparable as a European peer using donor-derived microbiota in standardized therapeutic products.
• Finch Therapeutics: Finch Therapeutics was a clinical-stage microbiome drug development company using Full-Spectrum Microbiota therapeutics for C. difficile and other conditions. It is a direct peer in donor-derived microbiome therapeutics, though it has undergone significant restructuring.
• OpenBiome: OpenBiome is a leading non-profit stool bank in the US that recruits and screens healthy donors to provide fecal microbiota transplants for clinical and research use. It is the most direct functional peer to Number 2, operating a similar donor recruitment, screening, and material processing model for microbiome therapeutics.
• BiomeBank: BiomeBank is an Australian-based microbiome therapeutics company that operates a stool bank and develops microbiome-based therapies. It is a direct regional peer with a similar donor-bank-plus-therapeutic-development model, though geographically focused on Australia.

Broad incumbents

• Rebiotix (Ferring Pharmaceuticals): Rebiotix, now part of Ferring Pharmaceuticals, developed the FDA-approved microbiome therapeutic Rebyota for recurrent C. difficile. It is a broad incumbent in microbiome therapeutics, operating under a much larger pharmaceutical company with broader resources and global reach.

Others

• EnteroBiotix Limited: EnteroBiotix Limited is the parent operating entity behind the Number 2 Donor Programme. It develops microbiome-based medicinal products from donor material, making it both the corporate owner and the primary downstream customer of the donor programme's output.

Emerging players

• Assembly Biosciences: Assembly Biosciences is a clinical-stage biotechnology company developing microbiome-based therapies for serious diseases. It is an emerging peer pursuing comparable therapeutic applications through microbiome engineering.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/number-2

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Number 2